|

Pralatrexate Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: Folotyn, Folotyn®

Pipeline

Phase 3: 2Phase 1/2: 1

Top Sponsors

  • University of Virginia1
  • Dizal Pharmaceuticals1
  • Corvus Pharmaceuticals, Inc.1

Indications

  • Cancer3
  • Lymphoma, T-Cell2
  • Peripheral T Cell Lymphoma1
  • Lymphoma, T-Cell, Peripheral1
  • Systemic Anaplastic Large Cell Lymphoma1

Other1 trial

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Phase 3

Duarte, California1 trial

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

City of Hope National Medical Center

Phase 3

Charlottesville, Virginia1 trial

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

University of Virginia

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.